Michael Schmainda, CEO of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics, and IQ-AI recently-appointed non-executive director, Dr Al Musella, discuss the latest developments at the company with Proactive’s Stephen Gunnion.
Schmainda discussed a renewed agreement with GE Healthcare, which streamlines the distribution of Imaging Biometrics’ IB Neuro and IB Delta T1 platforms. These tools aim to improve the assessment and treatment of brain tumours, offering radiologists more precise and actionable insights.
Schmainda emphasised that this partnership, involving a novel pricing model based on MRI scanners, could accelerate the adoption of the technology across GE’s extensive customer base. He also highlighted the potential impact on the market for treating high-grade gliomas and brain metastases.
Dr Musella shared his journey, from medical practitioner to advocate for brain tumour patients and the pivotal role Imaging Biometrics technology plays in improving treatment decisions. He discussed the expanded access program for gallium maltolate and the company’s focus on integrating its technology into clinical …